UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2018
Commission File Number: 0-30752
Aeterna Zentaris Inc.
(Translation of registrant's name into English)
315 Sigma Drive, Suite 302D Summerville, South Carolina, USA 29486
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______.
On April 9, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated April 9, 2018
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aeterna Zentaris Inc. | ||
| (Registrant) | ||
| Date: April 9, 2018 | /s/ MICHAEL V. WARD | |
| Michael V. Ward | ||
| CEO | ||
EXHIBIT 99.1
Aeterna Zentaris Files Management Information Circular
CHARLESTON, S.C., April 09, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) is pleased to announce that it has filed its Management Information Circular for the upcoming Annual and Special Meeting of Shareholders. The Meeting will be held at the offices of Stikeman Elliott LLP, located on the 41st floor at 1155 René-Lévesque Blvd. West, Montreal, Quebec, Canada, H3B 3V2 on Tuesday, May 8, 2018, at 10:00 a.m. (Eastern Time). Shareholders will receive the audited consolidated financial statements of the Corporation for the year ended December 31, 2017, together with the auditors’ report thereon and be asked to elect directors; to appoint auditors and to authorize the directors to determine their compensation; and to consider the ordinary resolution to approve the long-term incentive plan of the Corporation. The Management Information Circular is available on www.sedar.com, www.sec.gov and on the Company website www.aezsinc.com.
The Company encourages shareholders to read the Management Information Circular in detail. Shareholders who have questions or have not received their proxy or voting instruction form may contact Aeterna Zentaris’ Proxy Solicitation Agent:
| Laurel Hill Advisory Group | |||
| Toll free: 1-877-452-7184 or 416-304-0211 | |||
| Email: assistance@laurelhill.com |
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com.
Contacts:
Aeterna Zentaris Inc.
James Clavijo
Chief Financial Officer
IR@aezsinc.com
843-900-3201